French drugmaker Sanofi-Aventis and US group Regeneron Pharmaceuticals have extended their global partnership to discover, develop, and commercialise fully-human therapeutic monoclonal antibodies.
Read MoreDementia research in the UK was given a boost this week with the creation of a new ministerial group tasked with driving forward work into the causes, cure and care of the condition.
Read MoreBristol-Myers Squibb had dug deep into its pockets to sign a global commercialisation and development agreement for a monoclonal antibody owned by Alder Biopharmaceuticals, in a deal that could bring the latter firm over $1 billion.
Read MoreBristol-Myers Squibb was dealt a bitter blow last week after The High Court turned down its application for a judicial review of a decision by the National Institute for Health and Clinical Excellence that rejected Orencia for rheumatoid arthritis on the National Health Service.
Read MoreUK-based speciality pharmaceutical group BTG saw its purchase of Protherics pay off in a strong set of six-month results that showed swelling sales and gross profit despite a backdrop of difficult economic conditions.
Read More
